Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.27)
# 2,614
Out of 4,876 analysts
207
Total ratings
39.5%
Success rate
-1.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Overweight | $52 → $56 | $26.07 | +114.81% | 4 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $22.21 | +8.06% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $4.01 | +398.75% | 3 | May 19, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $64 → $65 | $37.13 | +75.06% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $183 → $166 | $107.59 | +54.29% | 6 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $7.28 | +133.52% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $3.59 | +847.08% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $61.58 | +16.92% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $49.55 | +41.27% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $126.71 | +18.38% | 26 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.26 | +217.46% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $54.13 | +57.03% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $7.75 | +351.61% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $13.04 | +107.06% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.36 | +14.68% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $33.91 | +97.58% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $5.69 | +110.90% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.11 | +392.61% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $29.99 | +133.41% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.86 | +365.12% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $7.95 | -49.69% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.80 | +400.69% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $3.19 | +338.87% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $2.70 | +85.19% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.02 | +194.12% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.40 | +900.00% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.91 | +423.56% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $43.09 | -48.94% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $14.74 | +907.46% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.75 | +3,323.68% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $2.97 | +102.02% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.46 | +11,639.13% | 6 | May 8, 2020 |
CG Oncology
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $26.07
Upside: +114.81%
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.21
Upside: +8.06%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $4.01
Upside: +398.75%
Ultragenyx Pharmaceutical
May 9, 2025
Maintains: Overweight
Price Target: $64 → $65
Current: $37.13
Upside: +75.06%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Overweight
Price Target: $183 → $166
Current: $107.59
Upside: +54.29%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $7.28
Upside: +133.52%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $3.59
Upside: +847.08%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $61.58
Upside: +16.92%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $49.55
Upside: +41.27%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $126.71
Upside: +18.38%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.26
Upside: +217.46%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $54.13
Upside: +57.03%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.75
Upside: +351.61%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $13.04
Upside: +107.06%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.36
Upside: +14.68%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $33.91
Upside: +97.58%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $5.69
Upside: +110.90%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $7.11
Upside: +392.61%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $29.99
Upside: +133.41%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.86
Upside: +365.12%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $7.95
Upside: -49.69%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.80
Upside: +400.69%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $3.19
Upside: +338.87%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $2.70
Upside: +85.19%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.02
Upside: +194.12%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.40
Upside: +900.00%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.91
Upside: +423.56%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $43.09
Upside: -48.94%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $14.74
Upside: +907.46%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.75
Upside: +3,323.68%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $2.97
Upside: +102.02%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.46
Upside: +11,639.13%